RICOH launches RICOH Standard DNA Series of reference DNA plates that overcome challenges in PCR testing

RCL and DNA Chip Research Inc. announced that today they will launch “RICOH Standard DNA Series EGFR mutation Type001”, a reference DNA plate jointly developed as reference material for use in accuracy control of blood-based genetic testing for lung cancer.

RICOH Standard DNA Series EGFR mutation Type001

This product contributes to improving the accuracy of testing by making it possible to confirm the accuracy of highly sensitive genetic testing that detects the very small amounts of DNA molecules from cancer cells that are contained in blood from lung cancer patients. Currently, these are only available in Japan, but they will be made available overseas in a sequential manner.

More information

About Ricoh

Ricoh is empowering digital workplaces using innovative technologies and services enabling individuals to work smarter. For more than 80 years, Ricoh has been driving innovation and is a leading provider of document management solutions, IT services, communications services, commercial and industrial printing, digital cameras, and industrial systems.

Headquartered in Tokyo, Ricoh Group operates in approximately 200 countries and regions. In the financial year ended March 2020, Ricoh Group had worldwide sales of 2,008 billion yen (approx. 18.5 billion USD).

For further information, please visit https://www.ricoh.co.th